Group 1 - The company China Antibody-B (03681) announced the issuance of 157 million subscription shares to the subscribers based on the subscription agreement on August 15, 2025 [1]

Group 1 - TCL Technology Group Co., Ltd. was established on July 17, 1997, and became a joint-stock company in 2002, listed on the Shenzhen Stock Exchange in 2004 [2] - The company plans to acquire 21.5311% equity of Shenzhen Huaxing Optoelectronics Technology Co., Ltd. through issuing shares and cash payment, as approved by the China Securities Regulatory Commission [2] - The company will issue 1,035,489,574 shares at a price of RMB 4.21 per share, increasing its registered capital to RMB 20,800,862,447 [2] Group 2 - As of August 8, 2025, the company has raised a total of RMB 4,300,995,724.98 after deducting issuance costs [2] - The total issuance costs amounted to RMB 61,920,304.45, with a net amount raised after costs being RMB 4,300,995,724.98 [2] - The main underwriter for the issuance is Shenwan Hongyuan Securities Co., Ltd., and the bank has confirmed the funds transferred to the company's account [2]

Group 1 - The company, Fourth Paradigm (06682), announced that all conditions of the placement agreement have been met, and the completion of the subscription agreement is set for August 14, 2025 [1] - A total of 25.9 million subscription shares have been issued at a subscription price of HKD 50.50 per share, representing approximately 8.78% of the issued H shares before completion and about 5.25% of the total issued shares [1] - The issuance of subscription shares will increase the total number of issued H shares by approximately 8.07% and the total issued shares by about 4.98% [1]

Group 1 - North Sea Kangcheng-B signed a subscription agreement with Baiyang Health Industry International Trade Co., Ltd. to issue 74.9715 million shares at HKD 1.34 per share, representing a discount of approximately 19.76% compared to the previous trading day's closing price [2] - The subscription is expected to raise HKD 100 million, with net proceeds estimated at approximately HKD 98.6618 million, which will be used for product research and development, marketing promotion, loan repayment, and daily operations [2] - The company's shares will be suspended from trading starting at 9:00 AM on August 12, 2025, and will resume trading at 9:00 AM on August 13, 2025 [2]

Core Viewpoint - The company, 北海康成-B (01228), has entered into a subscription agreement with 百洋健康产业国际商贸有限公司 to issue 74.9715 million shares at a subscription price of HKD 1.34 per share, representing a discount of approximately 19.76% from the closing price of HKD 1.67 on August 11, 2025 [1] Group 1 - The total amount raised from the subscription will be HKD 100 million, with a net amount estimated at approximately HKD 98.6618 million after deducting related expenses [1] - The net proceeds from the subscription are intended to be used for (i) research and development of commercialized products; (ii) marketing and promotional activities; (iii) repayment of loan financing and borrowings; and (iv) general operational activities of the group [1] - Trading of the company's shares was suspended on the Hong Kong Stock Exchange from 9:00 AM on August 12, 2025, at the request of the company, pending the announcement [1]

Core Viewpoint - North Sea Kangcheng-B (01228) has entered into a subscription agreement with Baiyang Health Industry International Trade Co., Ltd. to issue 74.9715 million subscription shares at a price of HKD 1.34 per share, representing a discount of approximately 19.76% from the closing price of HKD 1.67 on August 11, 2025 [1] Group 1 - The total amount raised from the subscription will be HKD 100 million, with a net amount estimated at approximately HKD 98.6618 million after deducting related expenses [1] - The net proceeds from the subscription will be used for (i) research and development of commercialized products; (ii) marketing and promotional activities; (iii) repayment of loan financing and borrowings; and (iv) daily operations of the group [1] - Trading of the shares has been suspended on the Hong Kong Stock Exchange from 9:00 AM on August 12, 2025, at the company's request, with a resumption of trading expected on August 13, 2025 [1]

Core Viewpoint - Feidao Tourism Technology (08069) plans to issue a total of 136 million shares to ASPECT, Inc., representing approximately 16.67% of the company's expanded issued share capital after the issuance [1] Group 1: Share Issuance Details - The subscription price is set at HKD 0.0306 per share, which is a discount of about 4.38% compared to the closing price of HKD 0.032 per share on August 1 [1] - The total amount raised from the subscription is approximately HKD 4.17 million, with a net amount of about HKD 4 million [1] Group 2: Use of Proceeds - The net proceeds are intended to be used for promoting the school travel market and the tourism industry [1]

Core Viewpoint - China Ruyi (00136) has announced a subscription agreement with Infinity Capital Management Limited, involving the conditional subscription of 1.3 billion shares at a price of HKD 3.00 per share, representing approximately 7.51% of the enlarged issued share capital [1] Group 1: Subscription Agreement Details - The subscription price of HKD 3.00 per share reflects a discount of approximately 4.46% compared to the closing price of HKD 3.14 on July 31, 2025 [1] - The total net proceeds from the subscription, after deducting related fees and expenses, are expected to be approximately HKD 38.95 billion [1] Group 2: Use of Proceeds - The company plans to allocate the net proceeds as follows: 20% for business growth and expansion, 60% for strategic investments and acquisitions to enhance the group's business, and 20% for general working capital purposes, including advertising, employee costs, technology development services, and rental costs [1]

Group 1 - The company plans to issue a total of 221.5 million shares to specific subscribers, which will represent approximately 12.12% of the enlarged issued share capital after the issuance [1] - The subscription price per share is set at HKD 0.10, reflecting a premium of about 44.93% compared to the closing price of HKD 0.069 on July 29 [1] - The total amount expected to be raised from this placement is HKD 22.15 million, with a net amount of approximately HKD 22.02 million [1] Group 2 - Approximately HKD 13.2 million of the raised funds will be used to repay overdue lease payments and other payables due within three months from the announcement date [1] - About HKD 8.8 million will be allocated for the company's general working capital [1]

待完成后，认购事项所得款项总额及所得款项净额预计将分别约为2215万港元及2202万港元。认购事项 的所得款项净额拟定用途为：约1320万港元用作偿还集团逾期应付租赁款项及其他将于本公布日期起3 个月内到期的未偿还债券应付款项及应付租赁款项;及约880万港元用作集团一般营运资金。 创业集团控股(02221)发布公告，于2025年7月29日，公司拟向认购人(沈定女士、赵素梅女士、黄智俊先 生、张红兵女士)配发及发行合共2.215亿股认购股份，相当于公司经配发及发行认购股份扩大后之已发 行股本的约12.12%。每股认购股份的认购价为0.10港元，较7月29日收市价每股股份0.069港元溢价约 44.93%。 ...